Clinical trials: Thalidomide
Multiple Myeloma
A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma
The purpose of this Phase 2 randomized study is to evaluate the efficacy and safety of treatment with a regimen of VELCADE, dexamethasone, and thalidomide (VDT) or VELCADE, dexamethasone, thalidomide, and cyclophosphamide (VDTC)…
- Trial name
- NCT00531453
- Testing
- bortezomib, dexamethasone, and thalidomide, bortezomib, dexamethasone, thalidomide, and cyclophosphamide
- Where
- Austria
- Volunteers
- 98 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
HIV Infections, Stomatitis, Aphthous
Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection
PRIMARY: To evaluate the effectiveness and safety of thalidomide for treatment of oral and esophageal aphthous ulcers (those unrelated to a known infection or malignancy) in patients with advanced HIV disease.
- Trial name
- NCT00000790
- Testing
- Thalidomide
- Where
- 40 sites in United States, Puerto Rico
- Volunteers
- 164 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Idiopathic Pulmonary Fibrosis (IPF)
Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide
The goal of this study is to determine whether thalidomide can stop the progression of fibrosis in IPF. The primary objective of this study is to determine the safety, feasibility and efficacy of 400 mg of thalidomide…
- Trial name
- NCT00162760
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Johns Hopkins University
Arteriovenous Malformation, Hereditary Hemorrhagic Telangiectasia
Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding
The purpose of this study is to determine whether Thalidomide is effective in the treatment of arteriovenous malformations in the gastrointestinal tract.
- Conditions
- Arteriovenous Malformation, Hereditary Hemorrhagic Telangiectasia, Hematochezia, Melena
- Trial name
- TAG (NCT00389935)
- Testing
- Thalidomide
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Northport Veterans Affairs Medical Center
Myelodysplastic Syndrome
Study of Velcade and Thalidomide in Patients With Myelodysplasia
The purpose of this study is to find out what the maximal tolerated dose of Velcade can be given with thalidomide in patients with myelodysplasia.
- Trial name
- NCT00271804
- Testing
- bortezomib
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Massachusetts General Hospital
Refractory Epilepsy
Thalidomide Low Threshold in Epilepsy
The purpose of this study is to determine whether thalidomide is effective in the refractory epilepsy treatment.
- Trial name
- NCT01061866
- Testing
- 3-phthalimidoglutarimide (Thalidomide)
- Volunteers
- 7 people
- Sponsor
- National Institute of Neurology and Neurosurgery, Mexico
Multiple Myeloma
Thalidomide-Dexamethasone for Multiple Myeloma
Objective is to assess the activity of the combination of thalidomide and dexamethasone in patients with previously untreated multiple myeloma.
- Trial name
- NCT00038090
- Testing
- Thalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- M.D. Anderson Cancer Center
Langerhans Cell Histiocytosis (LCH)
Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH
In adult patients with relapsed/refractory Langerhans cell histiocytosis (LCH), a treatment regimen of XTD regimen (Selinexor, Thalidomide and Dexamethasone) is planned to be used.
- Trial name
- NCT07204041
- Testing
- Selinexor, Thalidomide (100mg), Dexamethasone
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Myelofibrosis
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to…
- Trial name
- NCT04576156
- Testing
- Imetelstat, Best Available Therapy (BAT)
- Where
- 144 sites in United States, Argentina and 24 more
- Volunteers
- 327 people
- Sponsor
- Geron Corporation
Multiple Myeloma
Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide
The purpose of this study is determine Time-to-Progression with elotuzumab plus lenalidomide when elotuzumab is added to multiple myeloma participants with serologic relapse/progression while receiving lenalidomide maintenance…
- Trial name
- NCT03411031
- Testing
- Elotuzumab, Lenalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Intraocular Melanoma, Melanoma (Skin)
Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma
RATIONALE: Drugs used in chemotherapy, such as temozolomide and lomustine, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00072345
- Testing
- lomustine, temozolomide, thalidomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma
Toward improving the therapeutic index of standard TT3 (S-TT3), the investigators will employ a randomized Phase III trial design to determine whether S-TT3 treatment-related toxicities can be reduced by 50% in TT3-Lite (L-TT3).
- Trial name
- TT4B (NCT00734877)
- Testing
- M-VTD-PACE, TT3-LITE Regimen (L-TT3)
- Where
- United States
- Volunteers
- 382 people
- Sponsor
- University of Arkansas
Central Nervous System Tumor, Pediatric, Neuroblastoma
Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma
RATIONALE: Thalidomide may stop the growth of tumor cells by stopping blood flow to the tumor. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or…
- Trial name
- NCT00098865
- Testing
- temozolomide, thalidomide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Dana-Farber Cancer Institute
Thalassemia
The Effective and Safety of Thalidomide in NTDT
This is an exploratory experiment, aims to explore the effective and safety of thalidomide in the treatment of NTDT to improve the hemoglobin level, improve the quality of life, reduce blood transfusion, so as to avoid the…
- Trial name
- NCT02995707
- Testing
- Thalidomide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Xiao-Lin Yin
Carcinoma, Hepatocellular
A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)
Primary objective: To evaluate the overall response rate of tegafur/uracil (UFUR®) and thalidomide in the treatment of advanced or metastatic hepatocellular carcinoma. Secondary objectives: 1.
- Trial name
- NCT00384800
- Testing
- Thalidomide(THADO), Tegafur/Uracil(UFUR)
- Where
- Taiwan
- Volunteers
- 41 people
- Sponsor
- Far Eastern Memorial Hospital
Myeloma Multiple
Collection of Additional Data Followed the Study IFM 2013-04
Collection of retrospective additional data (survival, biological, disease response data) following the study IFM 2013-04.
- Trial name
- NCT03089411
- Where
- 63 sites in France
- Volunteers
- 340 people
- Sponsor
- Nantes University Hospital
Lung Cancer, Camrelizumab
A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
To explore and evaluate the safety and efficacy of camrelizumab combined with chemotherapy ± thalidomide in first-line treatment of advanced non-small cell lung cancer patients
- Trial name
- NCT06276933
- Testing
- Camrelizumab + chemotherapy+Thalidomide
- Volunteers
- 104 people
- Sponsor
- Tongji University
Endometrial Adenoacanthoma, Endometrial Adenocarcinoma
Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer
Phase II trial to study the effectiveness of thalidomide in treating patients who have recurrent or persistent endometrial cancer. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor
- Conditions
- Endometrial Adenoacanthoma, Endometrial Adenocarcinoma, Endometrial Adenosquamous Cell Carcinoma, Endometrial Clear Cell Carcinoma
- Trial name
- NCT00025467
- Testing
- thalidomide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to determine the effectiveness of thalidomide in treating patients who have asymptomatic, indolent non-Hodgkin's…
- Trial name
- NCT00052416
- Testing
- thalidomide
- Where
- 2 sites in United States
- Sponsor
- Beth Israel Deaconess Medical Center
Kidney Cancer
Interferon Alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
- Trial name
- NCT00027664
- Testing
- recombinant interferon alfa, thalidomide
- Where
- 3 sites in United Kingdom
- Volunteers
- 90 people
- Sponsor
- Cancer Research UK